2G, H, Supplementary Fig
Precisely 1 mL of ORI@CPD-Lipo, ORI@Lipo, or free ORI solution was transferred into a dialysis bag (molecular weight cutoff: 3500 Da), which was then sealed and immersed in 10 mL of phosphate buffer (pH 7.4) maintained at (37.0 0.5) C under constant shaking at 80 rpm
Considering that for both formulations, the gastrointestinal side effects were more frequent for higher doses, a dose-escalation scheme is appropriate and recommended to reduce the discontinuation rate
Instructions for use: It is recommended to take 2 capsules a day on a full stomach, away from coffee
Serious Side Effects (Less Common but Severe) Pancreatitis (inflammation of the pancreas) Gallbladder problems (gallstones) Kidney injury (due to dehydration from severe vomiting or diarrhea) Thyroid tumors (found in animal studies but unclear risk in humans) Hypoglycemia (low blood sugar) Additional Risks with Compounded Semaglutide Since compounded semaglutide lacks FDA approval and its formulation can vary, it may carry extra risks, including: A dose may be stronger or weaker than expected Affecting blood sugar control and weight loss
While CMSs approach to Medicare obesity drug coverage after the short-term Bridge program ends is unknown, a financially sustainable solution for how to cover GLP-1 drugs for obesity remains elusive.
.png?type=w800)
